Two phase 3 trials, namely PAOLA-1 and SOLO-1, have demonstrated the clinical efficacy of olaparib, with or without bevacizumab, in patients with homologous recombination deficiency (HRD)-positive or breast cancer gene (BRCA)-mutated advanced ovarian cancer (OC), leading to regulatory approval across multiple countries.1 In the latest long-term follow-up of the 2 trials, olaparib monotherapy and in combination with bevacizumab demonstrated clinically meaningful improvement in overall survival (OS) among the patients, consolidating its role as a first-line maintenance therapy in HRD-positive or BRCA-mutated advanced OC.1